Clinical Trials Browser

Phase 2/3 × INDUSTRY × glumetinib × Clear all

NCT06908772 2025-04-03

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Phase 2/3 Not yet recruiting

Recurrence